Efficacious recombinant influenza vaccines produced by high yield bacterial expression: a solution to global pandemic and seasonal needs.
It is known that physical linkage of TLR ligands and vaccine antigens significantly enhances the immunopotency of the linked antigens. We have used this approach to generate novel influenza vaccines that fuse the globular head domain of the protective hemagglutinin (HA) antigen with the potent TLR5 ligand, flagellin. These fusion proteins are efficiently expressed in standard E. coli fermentation systems and the HA moiety can be faithfully refolded to take on the native conformation of the globular head. In mouse models of influenza infection, the vaccines elicit robust antibody responses that mitigate disease and protect mice from lethal challenge. These immunologically potent vaccines can be efficiently manufactured to support pandemic response, pre-pandemic and seasonal vaccines.
Song
Langzhou
L
VaxInnate Corporation, Cranbury, New Jersey, United States of America. langzhou.song@vaxinnate.com
Nakaar
Valerian
V
Kavita
Uma
U
Price
Albert
A
Huleatt
Jim
J
Tang
Jie
J
Jacobs
Andrea
A
Liu
Ge
G
Huang
Yan
Y
Desai
Priyanka
P
Maksymiuk
Gail
G
Takahashi
Virginia
V
Umlauf
Scott
S
Reiserova
Lucia
L
Bell
Rodney
R
Li
Hong
H
Zhang
Yi
Y
McDonald
William F
WF
Powell
T J
TJ
Tussey
Lynda
L
D000818:Animals; D000914:Antibodies, Viral / Q000276:immunology; D004797:Enzyme-Linked Immunosorbent Assay; D000939:Epitopes / Q000737:chemistry / Q000276:immunology; D004926:Escherichia coli / Q000235:genetics; D009980:Influenza A virus / Q000276:immunology; D007252:Influenza Vaccines / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology; D051379:Mice; D009500:Neutralization Tests; D011487:Protein Conformation; D012621:Seasons; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology
D000914:Antibodies, Viral; D000939:Epitopes; D007252:Influenza Vaccines; D014614:Vaccines, Synthetic